AgomAb Therapeutics NV American Depositary Shares (AGMB)

About AGMB

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-44…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

62

Website

agomab.com/

Fundamentals

1-day range

$12.84$14.2

Market cap

$665.83M

P/E (trailing)

—

P/E (forward)

-6.36

EPS (trailing)

$-1.28

Dividend yield

—

Beta

1.44

Avg. volume

108.5K

Forecasts

6 analyst ratings

AgomAb Therapeutics NV American Depositary Shares Competitors

Chosen by industry and closest market cap.

• AGMB

  AgomAb Therapeutics NV American Depositary Shares

  $13.17

  ▼ 4.84%
  Market cap $665.83MP/E —
  $8.75$17.82
• ALLO

  Allogene Therapeutics Inc. Common Stock

  $2.01

  ▼ 3.83%
  Market cap $635.08MP/E —
  $1.04$4.46
• DNA

  Ginkgo Bioworks Holdings Inc. Class A Common Stock

  $6.98

  ▼ 3.93%
  Market cap $555.49MP/E —
  $5.37$17.58
• SLDB

  Solid Biosciences Inc. Common Stock

  $9.78

  ▼ 3.46%
  Market cap $789.57MP/E —
  $3.79$11.45
• FDMT

  4D Molecular Therapeutics Inc. Common Stock

  $14.65

  ▼ 1.74%
  Market cap $527.47MP/E —
  $5.97$16.93
• TECX

  Tectonic Therapeutic Inc. Common Stock

  $35.69

  ▼ 2.75%
  Market cap $526.83MP/E —
  $14.39$39.53
• ZURA

  Zura Bio Limited Class A Ordinary Shares

  $5.73

  ▼ 2.05%
  Market cap $524.39MP/E —
  $1.88$7.44

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60
  benzinga · 8/25/2026
• This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
  Benzinga · 8/25/2026
• Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60
  Benzinga · 8/25/2026
• This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
  Benzinga · 8/19/2026
• Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating
  Benzinga · 8/19/2026
• Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
  Yahoo · 8/10/2026
• Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
  Yahoo · 8/6/2026
• AgomAb Therapeutics H1 EPS $(0.93)
  Benzinga · 8/6/2026

Institutional Ownership

March 31, 2026

Total shares held

23.35M

Total value held

$245.05M

Institutional holders

32